{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:19:36Z","timestamp":1787897976709,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"The University of Osaka","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prognosis of marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains poor, even after R0 resection. JCOG0405 established preoperative cisplatin plus S-1 as a provisional standard of care in Japanese guidelines, based on a favorable 3-year overall survival (OS) of 58.8%. We report the 3-year survival outcomes of JCOG1704, a phase II trial evaluating preoperative docetaxel, oxaliplatin, and S-1 (DOS) for marginally resectable gastric cancer with ELM, following promising short-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with histologically confirmed HER2-negative gastric adenocarcinoma and bulky nodal (BN) involvement and\/or para-aortic node (PAN) metastasis were eligible. Patients received three cycles of DOS (docetaxel 40\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , day 1; oxaliplatin 100\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , day 1; S-1 80\u2013120\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , days 1\u201314) every 3\u00a0weeks, followed by gastrectomy with D2 plus PAN dissection and postoperative S-1 for 1\u00a0year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2018 and March 2022, 47 patients (BN only, 20; PAN only, 17; both, 10) were enrolled. At the data cutoff date (May 2025), the 3-year OS and progression-free survival (PFS) were 86.7% (95% CI 72.7\u201393.8%) and 75.6% (95% CI 60.2\u201385.6%), respectively, among 46 eligible patients. Among 42 patients who underwent R0 resection, the 3-year relapse-free survival (RFS) was 78.6% (95% CI 62.9\u201388.2%). In subgroup analyses, the 3-year OS\/PFS\/RFS were 85.0%\/75.0%\/77.8% in BN only, 93.8%\/81.3%\/86.7% in PAN only, and 77.8%\/66.7%\/66.7% in both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-026-01766-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:52:24Z","timestamp":1781081544000},"page":"1075-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704"],"prefix":"10.1007","volume":"29","author":[{"given":"Yukinori","family":"Kurokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souya","family":"Nunobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1766_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2022. https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&types=1 (accessed March 20, 2026)."},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ags3.12835","volume":"8","author":"T Higashi","year":"2024","unstructured":"Higashi T, Kurokawa Y. Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024. Ann Gastroenterol Surg. 2024;8:958\u201365.","journal-title":"Ann Gastroenterol Surg"},{"key":"1766_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ags3.12711","volume":"7","author":"Y Yanagimoto","year":"2023","unstructured":"Yanagimoto Y, Kurokawa Y, Doki Y. Essential updates 2021\/2022: perioperative and surgical treatments for gastric and esophagogastric junction cancer. Ann Gastroenterol Surg. 2023;7:698\u2013708.","journal-title":"Ann Gastroenterol Surg"},{"key":"1766_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S2468-1253(18)30090-6","volume":"3","author":"Y Kurokawa","year":"2018","unstructured":"Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3:460\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1766_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/bjs.6665","volume":"96","author":"T Yoshikawa","year":"2009","unstructured":"Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015\u201322.","journal-title":"Br J Surg"},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653\u201360.","journal-title":"Br J Surg"},{"key":"1766_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10120-019-01007-w","volume":"23","author":"D Takahari","year":"2020","unstructured":"Takahari D, Ito S, Mizusawa J, et al. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020;23:293\u20139.","journal-title":"Gastric Cancer"},{"key":"1766_CR8","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Yook JH, Park Y-K, et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1766_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16","author":"Y-K Kang","year":"2023","unstructured":"Kang Y-K, Kim H-D, Yook JH, et al. Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/jco.2023.41.16.","journal-title":"J Clin Oncol"},{"key":"1766_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ags3.12632","volume":"7","author":"Y Kurokawa","year":"2023","unstructured":"Kurokawa Y, Kawase T, Takeno A, et al. Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg. 2023;7:247\u201354.","journal-title":"Ann Gastroenterol Surg"},{"key":"1766_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fon-2019-0528","volume":"16","author":"Y Sato","year":"2020","unstructured":"Sato Y, Kurokawa Y, Doki Y, et al. A phase II study of preoperative chemotherapy with DOS in gastric cancer with extensive lymph node metastasis (JCOG1704). Future Oncol. 2020;16:31\u20138.","journal-title":"Future Oncol"},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27:366\u201374.","journal-title":"Gastric Cancer"},{"key":"1766_CR14","unstructured":"Green S, Benedetti J, Crowley J. The design of clinical trials. In: Clinical trials in oncology. 2nd ed. Boca Raton: Chapman & Hall\/CRC; 2003. p. 41\u201377."},{"key":"1766_CR15","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1766_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyad149","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Yanagimoto Y, Imazeki H, et al. Protocol digest of a randomized controlled adaptive Phase II\/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2024;54:206\u201311.","journal-title":"Jpn J Clin Oncol"},{"key":"1766_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative Durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330.","journal-title":"N Engl J Med"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01766-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:53:23Z","timestamp":1787896403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01766-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01766-3","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yukinori Kurokawa and Yuichiro Doki have received research funding from Taiho Pharmaceutical and Yakult Honsha, and lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib, MSD, Astellas Pharma, KAKEN Pharmaceutical, and Daiichi Sankyo outside of the submitted work. Junki Mizusawa has received lecture fees from Taiho Pharmaceutical, Chugai Pharmaceutical and Merck Biopharma outside of the submitted work; His spouse is an employee of Pfizer. Masanori Terashima has received lecture fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squib, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly, Pfizer, and Daiichi Sankyo outside of the submitted work. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Japanese Clinical Trials Act and the related regulations and with the 1964 Helsinki Declaration and its later amendments. Informed consent to be included in the study was obtained from all patients.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}